Merck Defeats Mylan's Challenge To Zetia, Vytorin Patent
A Merck & Co. Inc. unit prevailed Friday in a patent suit against Mylan Pharmaceuticals Inc. over its generic versions of cholesterol drugs Zetia and Vytorin, with a New Jersey federal...To view the full article, register now.
Already a subscriber? Click here to view full article